SAB Biotherapeutics (NASDAQ:SABS) Now Covered by Analysts at Rodman & Renshaw

Analysts at Rodman & Renshaw assumed coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. Rodman & Renshaw’s price objective indicates a potential upside of 235.92% from the company’s current price.

SABS has been the subject of several other research reports. Zacks Research downgraded shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Chardan Capital lifted their price target on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Wall Street Zen lowered shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. HC Wainwright decreased their target price on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Finally, UBS Group began coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, SAB Biotherapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.50.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $3.87 on Thursday. SAB Biotherapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $6.60. The company has a market capitalization of $197.18 million, a price-to-earnings ratio of -1.67 and a beta of 0.60. The stock has a fifty day moving average of $4.01 and a two-hundred day moving average of $3.53. The company has a debt-to-equity ratio of 0.02, a quick ratio of 9.46 and a current ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). On average, analysts anticipate that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of SABS. Vivo Capital LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter worth approximately $22,954,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics during the third quarter worth approximately $8,847,000. RA Capital Management L.P. purchased a new position in SAB Biotherapeutics during the third quarter worth approximately $8,847,000. Woodline Partners LP purchased a new position in SAB Biotherapeutics during the third quarter worth approximately $5,730,000. Finally, Spruce Street Capital LP acquired a new position in shares of SAB Biotherapeutics in the 4th quarter valued at $8,222,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.